Production of Inhibin-Related Peptides by Ovarian Tumors
Ovarian cancer is the most common fatal gynecological malignancy, responsible for more deaths than all other forms of gynecological cancer combined. Lifetime risks for development of the disease are estimated to lie in the range of 1 in 80 to 1 in 100, with a population prevalence of approximately 30 per 100,000 women. Most patients with the disease present at an advanced stage, with 30% surviving for 5 years with a diagnosis of stage 3 epithelial malignancy (representing local and pelvic extraperitoneal spread) while only 5%–10% survive with stage 4 disease (disseminated malignancy).
KeywordsOncol Activin Inhibin Cystadenomas Cystadenocarcinomas
Unable to display preview. Download preview PDF.
- 12.Sluijmer AV, Heineman MJ, Evers JLH, de Jong FH. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a postmenopausal patient with a granulosa cell tumour. Acta Endocrinol (Copenh) 1993;129:311–14.Google Scholar